Some aspects of pharmaceutical price regulation policy
Keywords:
pharmaceutical price regulation, price control, free pricing, reimbursement
Abstract
Worldwide trend of growing drugs expenditure with limited resources of health care system calls for policy decisions concern both supply of essential drugs and cost containment. The main strategic tools for price regulation in developed countries are pricing and reimbursement systems, which have direct and indirect impact on drug price respectively.
According to analysis, price regulation of drugs applies in all EU countries and Canada, but currently there is no a unified approach and most countries used combined pricing models.
This paper looks at the main models and approaches of price regulation of pharmaceuticals and most common pricing procedures. Also, article gives an overview of the authorities and organizations that are in charge of pricing and evaluation of therapeutic and economic benefit of drugs.
References
1. Reimbursement in Canada - How Does It Work ?: Round Table Discussion: Pricing and Reimbursement: International Experience and Topical Issues for Ukraine / Kohut M. // Pharmaceutical Industry Forum PHARMComplEX-2010, KyivExpoPlaza, 09/30/20I0
2. Yudanova A.Yu., Volskaya E. Regulation of prices as a function of the state // Pharmaceutical courier. - 2010. - №1. - P.53 - 61.
3. Calfee IS. Pharmaceutical price controls and patient welfare. / / Annals of Internal Medicine.
- 2001. - No. 134 (11). - R. 1060-1064.
4. DeGregorio S., Newman T. Health care Expenditure in Global Context. / / Benefits & Compensation International. - 2006. - №35 (8) - 2006. - P.1-6.
5. Dickson M. The pricing of pharmaceuticals: an international comparison. / / Clinical therapeutics. - 1992. - 14 (4). P. 604-610.
6. Espin J., Rovira J. Analysis of differences and commonalities in pricing and reimbursement systems in Europe. Final Report, 2007 - 22 p.
7. Ess S., Schneeweiss S., Szucs D.Thomas. European Healthcare Policies for Controlling Drug Expenditure // Pharmacoeconomics. - 2003. - №21 (2). - P.89-103.
8. Health Care System in Financing. The World Health Report. WHO, 2010 - 20p.
9. Khanolkar Vishakha, Khan Simeen A., Gamba Maria. An Insight on Health Care Expenditure // Proceedings of the academy of business economics. Chicago, Illinois MBAA Proceedings 2010
- Papers., Pp. 109-118
10. Monique F. Mrazek F. Comparative Approaches to the Pharmaceutical Price Regulation in the European Union // Croatia Medical Journal. - 2002. - №43 (4). R. 453-461
11. PPRI Austria Pharma Profile / Christine Leopold, Claudia Habl. - Vienna, 2008, 72 p.
12. PPRI Germany Pharma Profile / Tom Stargardt, Reinhard Busse, Hans-Peter Dauben. - Vienna, 2008, 60 p.
13. PPRI Glossary [Cited 2010, Jan 13]. - Available from: http://ppri.oebig.at/index. aspx? Navigation = r | 4-
14. PPRI Finland Pharma Profile / Sirpa Peura, Sinikka Rajaniemi, Ulla Kurkijdrvi. - Vienna, 2007, 60 p.
15. PPRI France Pharma Profile / Christine Leopold, Claudia Habl. - Vienna, 2008, 70 p.
16. PPRI Report / Sabine Vogler. - Vienna, 2008, 140 p. Available from: http://ppri.oebig.at/ Downloads / Publications / PPRI_Report_final.pdf
17. Roemer Milton I. Health Care Costs and Financing in the World Perspective // The Yale Journal of Biology and Medicine. - 1991. - No. 64. - R. 435-441.
18. Seiter Andreas. Pharmaceuticals: Cost containment, Pricing, Reimbursement. HNP Brief # 7, World Bank, 2005 - 7p. [Cited 2011, 13 Jan.]. - Available from: http://siteresources.worldbank.org/HEALTHNUTRITIONANDPOPULATION / Resources / 281627-1109774792596 / HNPBrief_7.pdf
19. Vlädescu C et al. Romania: Health system review. Health Systems in Transition, 2008. - Vol. 10, No. 1 3. - P 121-126.
20. Vogler S., Espin J., Hubble C. Pharmaceutical Pricing and Reimbursement Information (PPRI) - New PPRI analysis including Spain // Pharmaceuticals Policy and Law. - 2009. - № 11. - R. 213-234.
21. Der Weg ist frei für stabile Kassenfinanzen und eine neue Ordnung im Arzneimittelmarkt - zwei wichtige Gesetze passieren Bundesrat. // Press-mitteilung, 12/17/2010, Bundesministerium für Gesundheit. [Cited 2011, 13 Jan.] - Available from: http://www.bmg.bund.de/ministerium/presse/ pressemitteilungen / 2010-04 / wichtige-gesetze-passieren-bundesrat.html
2. Yudanova A.Yu., Volskaya E. Regulation of prices as a function of the state // Pharmaceutical courier. - 2010. - №1. - P.53 - 61.
3. Calfee IS. Pharmaceutical price controls and patient welfare. / / Annals of Internal Medicine.
- 2001. - No. 134 (11). - R. 1060-1064.
4. DeGregorio S., Newman T. Health care Expenditure in Global Context. / / Benefits & Compensation International. - 2006. - №35 (8) - 2006. - P.1-6.
5. Dickson M. The pricing of pharmaceuticals: an international comparison. / / Clinical therapeutics. - 1992. - 14 (4). P. 604-610.
6. Espin J., Rovira J. Analysis of differences and commonalities in pricing and reimbursement systems in Europe. Final Report, 2007 - 22 p.
7. Ess S., Schneeweiss S., Szucs D.Thomas. European Healthcare Policies for Controlling Drug Expenditure // Pharmacoeconomics. - 2003. - №21 (2). - P.89-103.
8. Health Care System in Financing. The World Health Report. WHO, 2010 - 20p.
9. Khanolkar Vishakha, Khan Simeen A., Gamba Maria. An Insight on Health Care Expenditure // Proceedings of the academy of business economics. Chicago, Illinois MBAA Proceedings 2010
- Papers., Pp. 109-118
10. Monique F. Mrazek F. Comparative Approaches to the Pharmaceutical Price Regulation in the European Union // Croatia Medical Journal. - 2002. - №43 (4). R. 453-461
11. PPRI Austria Pharma Profile / Christine Leopold, Claudia Habl. - Vienna, 2008, 72 p.
12. PPRI Germany Pharma Profile / Tom Stargardt, Reinhard Busse, Hans-Peter Dauben. - Vienna, 2008, 60 p.
13. PPRI Glossary [Cited 2010, Jan 13]. - Available from: http://ppri.oebig.at/index. aspx? Navigation = r | 4-
14. PPRI Finland Pharma Profile / Sirpa Peura, Sinikka Rajaniemi, Ulla Kurkijdrvi. - Vienna, 2007, 60 p.
15. PPRI France Pharma Profile / Christine Leopold, Claudia Habl. - Vienna, 2008, 70 p.
16. PPRI Report / Sabine Vogler. - Vienna, 2008, 140 p. Available from: http://ppri.oebig.at/ Downloads / Publications / PPRI_Report_final.pdf
17. Roemer Milton I. Health Care Costs and Financing in the World Perspective // The Yale Journal of Biology and Medicine. - 1991. - No. 64. - R. 435-441.
18. Seiter Andreas. Pharmaceuticals: Cost containment, Pricing, Reimbursement. HNP Brief # 7, World Bank, 2005 - 7p. [Cited 2011, 13 Jan.]. - Available from: http://siteresources.worldbank.org/HEALTHNUTRITIONANDPOPULATION / Resources / 281627-1109774792596 / HNPBrief_7.pdf
19. Vlädescu C et al. Romania: Health system review. Health Systems in Transition, 2008. - Vol. 10, No. 1 3. - P 121-126.
20. Vogler S., Espin J., Hubble C. Pharmaceutical Pricing and Reimbursement Information (PPRI) - New PPRI analysis including Spain // Pharmaceuticals Policy and Law. - 2009. - № 11. - R. 213-234.
21. Der Weg ist frei für stabile Kassenfinanzen und eine neue Ordnung im Arzneimittelmarkt - zwei wichtige Gesetze passieren Bundesrat. // Press-mitteilung, 12/17/2010, Bundesministerium für Gesundheit. [Cited 2011, 13 Jan.] - Available from: http://www.bmg.bund.de/ministerium/presse/ pressemitteilungen / 2010-04 / wichtige-gesetze-passieren-bundesrat.html
Published
2019-07-01
How to Cite
Datsiuk, N., Kheilomskyi, O., & Sholoiko, N. (2019). Some aspects of pharmaceutical price regulation policy. Farmatsevtychnyi Zhurnal, (2), 23-30. Retrieved from https://pharmj.org.ua/index.php/journal/article/view/672
Section
Monitoring of drug prices
This work is licensed under a Creative Commons Attribution 4.0 International License.
